Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
-
Publication number: 20140205595Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Inventors: Youyi Peng, Lawrence P. Wennogle, Qing Zhang, John Tomesch
-
Patent number: 8785470Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.Type: GrantFiled: July 18, 2012Date of Patent: July 22, 2014Assignee: Infinity Pharmaceuticals, Inc.Inventors: Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Daniel A. Snyder, Martin R. Tremblay, Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan
-
Patent number: 8778914Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.Type: GrantFiled: August 24, 2010Date of Patent: July 15, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Katrin Hochdoerffer
-
Publication number: 20140193519Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: August 2, 2013Publication date: July 10, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Barbara P. Wallner, Brian Eric Schwartz, Philip B. Komarnitsky, Gerald Bacher, Bernhard Kutscher, Gerhard Raab
-
Publication number: 20140194458Abstract: Provided is a 10-methoxycamptothecine derivate of formula (1), wherein R is selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl substituted C1-6 alkyl, phosphate substituted C1-6 alkyl, amino-substituted C1-6 alkyl, carboxyl substituted C1-6 alkyl, hydroxyl substituted C1-6 alkyl, and amide- substituted C1-6 alkyl; R1 is selected from hydrogen and t-butoxycarbonyl substituted amino. Also provided in the present invention are the preparation method of the derivate and the use thereof in anti-tumor drug preparation.Type: ApplicationFiled: June 15, 2012Publication date: July 10, 2014Applicant: Northeast Forestry UniversityInventors: Yang Wang, Xiufeng Yan, Lijia Jing, Weimin Ding, Jian Zheng, Qiuying Pang, Tao Yu
-
Publication number: 20140186367Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: ApplicationFiled: February 4, 2014Publication date: July 3, 2014Applicant: The University of ChicagoInventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
-
Patent number: 8765173Abstract: A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises poorly water soluble nanoparticles formed by the API together with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer.Type: GrantFiled: December 18, 2008Date of Patent: July 1, 2014Assignee: Ardenia Investments, Ltd.Inventors: Julian Aleksov, Igor Lokot
-
Patent number: 8765432Abstract: The present invention provides random copolymers containing phosphorylcholine and one or more functional agents, and methods of preparing such random copolymers.Type: GrantFiled: May 10, 2010Date of Patent: July 1, 2014Assignee: Oligasis, LLCInventors: Stephen A. Charles, D. Victor Perlroth
-
Publication number: 20140178354Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: December 23, 2013Publication date: June 26, 2014Applicant: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Patent number: 8759375Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.Type: GrantFiled: January 14, 2013Date of Patent: June 24, 2014Assignee: Celgene CorporationInventor: Jerome B. Zeldis
-
Patent number: 8758830Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: August 23, 2013Date of Patent: June 24, 2014Assignee: Array BioPharma, Inc.Inventors: Yvan Le Huerou, James F. Blake, Indrani W. Gunawardana, Peter J. Mohr, Eli M. Wallace, Bin Wang, Mark Joseph Chicarelli, Michael Lyon
-
Patent number: 8754078Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.Type: GrantFiled: February 7, 2013Date of Patent: June 17, 2014Assignee: ArQule, Inc.Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, Neru Munshi
-
Patent number: 8754121Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.Type: GrantFiled: August 19, 2011Date of Patent: June 17, 2014Assignee: Academia SinicaInventors: Lie-Fen Shyur, Wen-Wan Chao, Ya-Wen Cheng
-
Publication number: 20140162996Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.Type: ApplicationFiled: July 29, 2013Publication date: June 12, 2014Applicant: CITY OF HOPEInventors: Samuel RAHBAR, James L. FIGAROLA, Christopher LINCOLN, David HORNE, Rachael MOONEY, Monika POLEWSKI, George SOMLO, Lixin YANG
-
Publication number: 20140162969Abstract: There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumour, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumours are also provided.Type: ApplicationFiled: February 14, 2014Publication date: June 12, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Yiqing TANG, Peter William STRATFORD
-
Patent number: 8748449Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.Type: GrantFiled: July 9, 2012Date of Patent: June 10, 2014Assignee: Alfa Wassermann S.p.A.Inventors: Paola Maffei, Milena Bachetti, Giuseppe Bottoni, Giuseppe Claudio Viscomi
-
Patent number: 8747891Abstract: Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.Type: GrantFiled: May 10, 2012Date of Patent: June 10, 2014Assignee: The Penn State Research FoundationInventors: Mark Kester, Sriram S. Shanmugavelandy, Todd Fox
-
Patent number: 8735394Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.Type: GrantFiled: May 6, 2009Date of Patent: May 27, 2014Assignee: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20140140931Abstract: This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and anti-oxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs.Type: ApplicationFiled: July 27, 2012Publication date: May 22, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: John S. Yu, Bong Seop Lee
-
Publication number: 20140141089Abstract: The disclosure is directed to a nanoparticle comprising a porous framework core including a porous framework material and a compound, and a lipid layer disposed on the surface of the porous framework core.Type: ApplicationFiled: February 11, 2010Publication date: May 22, 2014Applicant: Colorado School of MinesInventor: Hongjun Liang
-
Patent number: 8729048Abstract: This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided.Type: GrantFiled: November 16, 2012Date of Patent: May 20, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Scott H. Kaufmann, Anand G. Patel
-
Publication number: 20140135356Abstract: The present invention provides novel conjugates of camptothecin and camptothecin analogs with a linker and an HSA-binding moiety. The novel conjugates are prodrug forms of the camptothecin or camptothecin analogs and can be used to treat mammalian cell proliferative diseases, such as cancer.Type: ApplicationFiled: November 11, 2013Publication date: May 15, 2014Applicant: FL Therapeutics, LLCInventor: Qun Sun
-
Publication number: 20140134280Abstract: An extract of Cynanchum sp. in use of arthritis treatment is provided. The extract of Cynanchum sp. and an active ingredient contained therein, antofine, are applicable to a method, pharmaceutical composition and dietary supplement for treatment of arthritis. A mass production of antofine from plant extracts is also provided.Type: ApplicationFiled: April 27, 2012Publication date: May 15, 2014Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jennline Sheu, Lain-Tze Lee, Ying-Chu Shih, Cheng-Yu Lee, Yi-Ching Lee, Jir-Mehng Lo, Tien-Soung Tong, Jui-Hung Yen, Kuo-Kuei Huang, Ying-Fei Tsai
-
Publication number: 20140134274Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.Type: ApplicationFiled: October 24, 2013Publication date: May 15, 2014Applicant: University of Tennessee Research FoundationInventors: Mitchell S. Steiner, Mary Ann Johnston, Michael L. Hancock, Jeffrey G. Hesselberg, James T. Dalton
-
Publication number: 20140135357Abstract: The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.Type: ApplicationFiled: November 12, 2013Publication date: May 15, 2014Applicants: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.Inventors: Yun-Long TSENG, Keelung HONG, Min-Wen KUO
-
Publication number: 20140127136Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.Type: ApplicationFiled: January 9, 2014Publication date: May 8, 2014Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Daryl C. Drummond, Dmitri Kirpotin
-
Publication number: 20140128421Abstract: Provided are a camptothecin compound containing 7-membered lactone ring, as shown in general formula I, and pharmaceutically acceptable salt thereof, as well as the preparation method and use thereof. In general formula I, R1 is H, a C1˜C3 alkyl, acetyl or propionyl; R2 is H, a C1˜C6 alkyl, a C3˜C6 cycloalkyl, piperidyl; or a C1˜C6 alkyl substituted by an amino; R3 is H, a C1˜C3 alkyl, or a C1˜C6 alkyl substituted by an amino; R4 is H, a hydroxyl, or a C1˜C6 alkoxy; R5 is H, or a C1˜C6 alkoxyl; or R4 and R5 are linked to each other to form —OCH2O— or —OCH2CH2O—. The compound has good anti-tumor activity, and can be clinically used via oral administration, intravenous injection, and intramuscular injection, among others.Type: ApplicationFiled: April 13, 2012Publication date: May 8, 2014Applicants: EAST CHINA NORMAL UNIVERSITY, NANJING LUYESKIE PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Wei Lv, Shanbao Yu, Yu Luo, Yi Chen, Jian Ding
-
Publication number: 20140127272Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.Type: ApplicationFiled: October 31, 2013Publication date: May 8, 2014Applicant: Cedars-Sinai Medical CenterInventors: John S. Yu, Bong Seop Lee
-
Publication number: 20140120087Abstract: The present invention relates to triazolopyridine compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: April 16, 2012Publication date: May 1, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Volker Schulze, Dirk Kosemund, Antje Margret Wengner, Gerhard Siemeister, Detlef Stöckigt, Philip Lienau, Hartmut Schirok, Hans Briem
-
Publication number: 20140121178Abstract: The present invention relates to a method and an improved composition for improving the absorption of an ester prodrug in a subject. The method includes co-administering to the subject an effective amount of the ester prodrug or a pharmaceutical acceptable salt thereof, and a sufficient amount of adjuvant to impede a carboxylesterase-mediated hydrolysis of the ester prodrug in vivo, wherein the adjuvant is selected from the gnzup consisting of triacetin, triethyl citrate and a combination of both. The present invention also relates to a method for impeding carboxylesterase-mediated hydrolysis of esters, including ester prodrugs.Type: ApplicationFiled: June 24, 2011Publication date: May 1, 2014Applicant: ACENDA PHARMA INC.Inventor: Haiyung Cheng
-
Patent number: 8709474Abstract: The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.Type: GrantFiled: December 9, 2012Date of Patent: April 29, 2014Assignee: BC Cancer AgencyInventors: Marcel Bally, Euan Ramsay
-
Patent number: 8709419Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.Type: GrantFiled: August 10, 2011Date of Patent: April 29, 2014Assignee: Hoffmann-La Roche, Inc.Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
-
Publication number: 20140113879Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: September 16, 2013Publication date: April 24, 2014Applicant: Intezyne Technologies, Inc.Inventors: Adam Carie, Kevin Sill
-
Patent number: 8703181Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.Type: GrantFiled: October 17, 2012Date of Patent: April 22, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
-
Publication number: 20140107147Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.Type: ApplicationFiled: May 2, 2013Publication date: April 17, 2014Applicant: Wyeth LLCInventor: Wyeth LLC
-
Publication number: 20140093585Abstract: The present invention relates to the method of treating chemotherapy-induced neuropathy in a subject in need thereof with the use of a poly(ADP-ribose)polymerase (PARP) inhibitor.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Inventors: Vincent L. Giranda, Alexander R. Shoemaker, Kaitlin E. Browman, Shailen K. Joshi, Jill-Desiree Brederson
-
Patent number: 8685997Abstract: New camptothecin derivatives with the following structure of the formula (I), their use and the pharmaceutical compositions containing the same. The compounds of the present invention have good anti-tumor activities and good solubility in water, and can be used in development of medicines.Type: GrantFiled: January 17, 2007Date of Patent: April 1, 2014Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Wei Lu, Jian Ding, Heyong Gao, Liping Lin, Yi Chen
-
Publication number: 20140088133Abstract: The present invention provides compounds (such as compounds of formula I-a) that induce ? globin expression and pharmaceutical compositions thereof. Such compounds may have beneficial therapeutic effects. Compounds and compositions described herein may be used to treat hemoglobinopathies such as ?-thalassemia and sickle cell anemia.Type: ApplicationFiled: January 3, 2012Publication date: March 27, 2014Applicant: Academia SinicaInventors: Che-Kun James Shen, Yu-Chi Chou
-
Publication number: 20140079644Abstract: In one aspect, there is provided a compound comprising an acetylated carboxymethylcellulose (CMC-Ac) covalently linked to: at least one poly(ethylene glycol) (PEG), and at least one hydrophobic drug. In another aspect, a self-assembling nanoparticle composition comprising such compounds is provided.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCHInventors: Shyh-Dar Li, Mark John Ernsting, Wei-Lun Tang
-
Publication number: 20140079693Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: ApplicationFiled: November 15, 2013Publication date: March 20, 2014Applicant: NOVARTIS AGInventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
-
Publication number: 20140079636Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to an binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.Type: ApplicationFiled: March 15, 2013Publication date: March 20, 2014Inventors: Dinesh U. Chimmanamada, Weiwen Ying
-
Publication number: 20140073604Abstract: Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Applicant: UNIVERSITY OF NORTH CAROLINA AT WILMINGTONInventor: UNIVERSITY OF NORTH CAROLINA AT WILMINGTON
-
Patent number: 8663700Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: GrantFiled: June 11, 2013Date of Patent: March 4, 2014Assignee: BIND Therapeutics, Inc.Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
-
Patent number: 8663606Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: GrantFiled: October 21, 2011Date of Patent: March 4, 2014Assignee: Medigene AGInventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
-
Publication number: 20140056880Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.Type: ApplicationFiled: August 28, 2013Publication date: February 27, 2014Applicant: NOVARTIS AGInventors: Tinya Abrams, Paul Barsanti, Yu Ding, David Duhl, Wooseok Han, Cheng Hu, Yue Pan
-
Patent number: 8652528Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: GrantFiled: April 12, 2013Date of Patent: February 18, 2014Assignee: BIND Therapeutics, Inc.Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
-
Publication number: 20140045782Abstract: Methods of treating cancer by administering a DNA damaging agent and a CHK1 Inhibitor on a dosing regimen are provided.Type: ApplicationFiled: June 7, 2013Publication date: February 13, 2014Inventors: Michael J. Humphries, Shannon L. Winski
-
Publication number: 20140037547Abstract: The present invention relates to cGMP protein kinase (PKG) and regulatory domains and methods of use thereof. The structural determination of PKG domains is also described. cGMP independent PKG activators and uses thereof are also described.Type: ApplicationFiled: March 13, 2013Publication date: February 6, 2014Applicant: The University of Vermont and State Agricultural CollegeInventors: Wolfgang Dostmann, Brent W. Osborne, Thomas M. Moon
-
Publication number: 20140037620Abstract: The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the therapy in subjects when it is found that gemcitabine is likely to be effective.Type: ApplicationFiled: June 28, 2013Publication date: February 6, 2014Inventors: Sean M. Ferree, J. Wayne Cowens, Charlotte Levin Tykjaer Jorgensen, Torsten O. Nielsen, Bent Ejlertsen
-
Publication number: 20140030224Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.Type: ApplicationFiled: April 10, 2012Publication date: January 30, 2014Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex